Brief: Schrödinger’S Statement Regarding FDA Plan To Phase Out Animal Testing Requirement For Monoclonal Antibodies And Other Drugs
14/04/2025 13:32
April 14 (Reuters) - Schrodinger Inc SDGR.O: SCHRÖDINGER’S STATEMENT REGARDING FDA PLAN TO PHASE OUT ANIMAL TESTING REQUIREMENT FOR MONOCLONAL ANTIBODIES AND OTHER DRUGS SCHRODINGER INC - SCHRÖDINGER SUPPORTS FDA PLAN TO REDUCE ANIMAL TESTING REQUIREMENTS SCHRODINGER INC - PREDICTIVE TOXICOLOGY SOLUTION EXPECTED TO LAUNCH IN H2 2025 Source text: ID:nBw6Frfx6a Further company coverage: SDGR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Schrodinger
See all newsBrief: Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Schrodinger Inc reports results for the quarter ended June 30 - Earnings Summary
Schrodinger Q2 revenue beats estimates, swings to profit
Brief: Schrodinger Q2 Revenue USD 58.889 Million Vs. IBES Estimate USD 47.2 Million
Brief: Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)